传

Dr. Olson is an Assistant Professor at the University of Texas Health Science Center in the Department of Pediatric Surgery. Dr. Olson completed his doctorate in the lab of Dr. Darwin Prockop at Tulane University’s Center for Gene Therapy studying novel methods by which mesenchymal stem cells (MSC) can contribute to tissue repair. At University of California at Davis’s Health Sciences Institute for Regenerative Cures, Dr. Olson worked to apply MSC as a platform to develop new treatments for Huntington’s Disease. Dr. Olson joined UTHealth in September 2011.

Dr. Olson is an academic researcher with experience developing studies with translational applications. At UT Health, his primary focus is bringing his expertise in the field of adult stem cells, specifically MSC, to explore their potential in the treatment of Traumatic Brain Injury (TBI). MSC have been used in a number of completed, ongoing, and proposed clinical trials with reported therapeutic benefits. Dr. Olson strives to better describe the role of MSC in TBI injuries, highlighting their innate therapeutic abilities in an effort to create an improved treatment for TBI.

教育

BS
Biochemistry - Texas Christian University, Fort Worth, TX
PhD
Molecular and Cellular Biology - Tulane University, New Orleans, LA
博士后
Stem Cell Program - University of California at Davis Health System, Sacramento, CA

Areas of Interest

Research Interests

Mese的转化研究nchymal Stem Cells, Translational Laboratories

beplay苹果手机能用吗研究信息

  • 细胞疗法中的间充质干细胞免疫调节并恢复体内平衡
    Mesenchymal stem cells (MSCs) have been used in a large number of clinical trials to treat a wide variety of diseases and injuries with some success. When viewed as a whole, MSC have been most efficacious when used in a situation where there is a secondary or chronic injury associated with prolonged or exaggerated inflammation, perhaps due to their impressive ability to control the activation of the immune system systemically and in local microenvironments. We hypothesize that as we better understand the mechanisms by which MSC can exert their effects, we can begin to rethink and redesign cellular therapies to amplify their efficacy while increasing their safety.
  • 比较MSC准备
    作为我们确定蜂窝疗法最佳候选者的全球努力的一部分，我们正在使用来自不同组织甚至商业来源的许多相似但不同的MSC和MSC样细胞。我们的小组一直在设计和执行许多旨在探索哪些生物标志物或体外我们可能能够用来预测配对的治疗效率的测定体内studies in collaboration with Drs. Triolo and Cox. These studies are initially focusing upon efficacy in models of Traumatic Brain Injury, but will expand later into other diseases and injuries with significant inflammatory elements.
  • MSC-effector cell interactions
    此外，我们着重于MSC与源自脾脏中的循环外周血单核细胞和白细胞的特定免疫细胞种群的相互作用。我们对MSC影响单核细胞和巨噬细胞表型的能力特别感兴趣，以及其分泌组的变化可能会钝化炎症甚至恢复全系统稳态。
  • 混合细胞制剂作为治疗
    A large part of the therapeutic value of MSC therapies relies upon the interactions that MSC have with the host immune system. To this end, we aim to augment the efficacy of MSC by introducing them directly to effector cellsex vivoand then shielding the resulting cells from immune recognition that may lead to rejection. In this manner, we hypothesize that we can create a systemic-style response inside an implantable construct that can be placed in the vulnerable microenvironment using a selectively permeable, non-toxic scaffold.

Publications

Publication Information

Joyce N，Annett G，Wirthlin L，Olson S，Bauer G，Nolta J.间充质茎
用于治疗神经退行性疾病的细胞。再生医学
2010 5(6).

Meyerrose T，Olson S，Pontow S，Kalomoiris S，Jung Y，Annett G，Bauer G，
Nolta Ja。间充质干细胞，用于持续的生物活性体内递送
因素。Adv Drug Deliv Rev. 2010年9月30日； 62（12）：1167-74。Epub 2010年10月13日。

Gruenloh W, Kambal A, Sondergaard C, McGee J, Fierro F, Olson SD, Nolta JA.
源自源自的间充质干细胞的表征和体内测试
human embryonic stem cells. Tissue Eng Part A. 2011 Mar 4.

Olson SD, Kambal A, Mitchell G, Pollock, K, Mitchell G, Stewart H, Kalomoiris,
S, Cary W, Nacey C, Pepper K, Nolta JA. Intercellular Examination of
mesenchymal stem cell-mediated RNAi transfer to Huntington’s disease affected
neuronal cells for reduction of huntingtin. Molecular and Cellular Neuroscience.
MS in review, 8/2011.

Olson SD, Pollock K, Kambal A, Cary W, Mitchell G, Tempkin J, Stewart H,
McGee J, Bauer G, Tempkin T, Wheelock V, Annett G, Dunbar G, Nolta JA..
基因设计的间充质干细胞作为提出的治疗性
Huntington’s disease. Molecular Neurobiology. MS in resubmission 9/2011.

Olson SD*, McNerny G*, Pollock K, Huser T, Nolta JA. siRNA and RISC proteins
directly visualized using super-high resolution microscopy. MS in preparation, Oct 2011. *equal contributors